150 related articles for article (PubMed ID: 7657853)
1. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174.
Christ DD
J Clin Pharmacol; 1995 May; 35(5):515-20. PubMed ID: 7657853
[TBL] [Abstract][Full Text] [Related]
2. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174.
Yun CH; Lee HS; Lee H; Rho JK; Jeong HG; Guengerich FP
Drug Metab Dispos; 1995 Feb; 23(2):285-9. PubMed ID: 7736926
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent.
Wong PC; Price WA; Chiu AT; Duncia JV; Carini DJ; Wexler RR; Johnson AL; Timmermans PB
J Pharmacol Exp Ther; 1990 Oct; 255(1):211-7. PubMed ID: 2213556
[TBL] [Abstract][Full Text] [Related]
4. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist.
Munafo A; Christen Y; Nussberger J; Shum LY; Borland RM; Lee RJ; Waeber B; Biollaz J; Brunner HR
Clin Pharmacol Ther; 1992 May; 51(5):513-21. PubMed ID: 1587065
[TBL] [Abstract][Full Text] [Related]
5. DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.
Goldberg MR; Lo MW; Christ DD; Chiou R; Furtek CI; Amit O; Carides A; Biollaz J; Piguet V; Nussberger J; Brunner HR
Clin Pharmacol Ther; 1997 Jan; 61(1):59-69. PubMed ID: 9024174
[TBL] [Abstract][Full Text] [Related]
6. Different types of receptor interaction of peptide and nonpeptide angiotensin II antagonists revealed by receptor binding and functional studies.
Wienen W; Mauz AB; Van Meel JC; Entzeroth M
Mol Pharmacol; 1992 Jun; 41(6):1081-8. PubMed ID: 1614410
[TBL] [Abstract][Full Text] [Related]
7. EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells.
Sachinidis A; Ko Y; Weisser P; Meyer zu Brickwedde MK; Düsing R; Christian R; Wieczorek AJ; Vetter H
J Hypertens; 1993 Feb; 11(2):155-62. PubMed ID: 8385175
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans.
Lo MW; Goldberg MR; McCrea JB; Lu H; Furtek CI; Bjornsson TD
Clin Pharmacol Ther; 1995 Dec; 58(6):641-9. PubMed ID: 8529329
[TBL] [Abstract][Full Text] [Related]
9. Effects of losartan on vasoconstrictor responses to angiotensin II in the forearm vascular bed of healthy volunteers.
Baan J; Chang PC; Vermeij P; Pfaffendorf M; van Zwieten PA
Cardiovasc Res; 1996 Nov; 32(5):973-9. PubMed ID: 8944829
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography.
Furtek CI; Lo MW
J Chromatogr; 1992 Jan; 573(2):295-301. PubMed ID: 1601963
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II receptor antagonists. From discovery to antihypertensive drugs.
Timmermans PB; Carini DJ; Chiu AT; Duncia JV; Price WA; Wells GJ; Wong PC; Wexler RR; Johnson AL
Hypertension; 1991 Nov; 18(5 Suppl):III136-42. PubMed ID: 1937677
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effects of DuP 753 and EXP3174 on responses to angiotensin II in pulmonary vascular bed of the cat.
McMahon TJ; Kaye AD; Hood JS; Minkes RK; Nossaman BD; Kadowitz PJ
J Appl Physiol (1985); 1992 Nov; 73(5):2054-61. PubMed ID: 1474085
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with angiotensin II receptor antagonists.
Brunner HR; Christen Y; Munafo A; Lee RJ; Waeber B; Nussberger J
Am J Hypertens; 1992 Dec; 5(12 Pt 2):243S-246S. PubMed ID: 1290619
[TBL] [Abstract][Full Text] [Related]
15. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
[TBL] [Abstract][Full Text] [Related]
16. Binding of [3H]angiotensin II and [3H]DuP 753 (Losartan) to rat liver homogenates reveals multiple sites. Relationship to AT1a- and AT1b-type angiotensin receptors and novel nonangiotensin binding sites.
Widdowson PS; Renouard A; Vilaine JP
Peptides; 1993; 14(4):829-37. PubMed ID: 8234032
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptide angiotensin II receptor antagonist: pharmacokinetics and pharmacodynamics in rats of EXP3174, an active metabolite of losartan.
Wong PC; Christ DD; Wong YN; Lam GN
Pharmacology; 1996 Jan; 52(1):25-9. PubMed ID: 8966199
[TBL] [Abstract][Full Text] [Related]
18. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist.
Siegl PK; Chang RS; Mantlo NB; Chakravarty PK; Ondeyka DL; Greenlee WJ; Patchett AA; Sweet CS; Lotti VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):139-44. PubMed ID: 1625193
[TBL] [Abstract][Full Text] [Related]
19. Binding of valsartan to mammalian angiotensin AT1 receptors.
de Gasparo M; Whitebread S
Regul Pept; 1995 Nov; 59(3):303-11. PubMed ID: 8577935
[TBL] [Abstract][Full Text] [Related]
20. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
